IBA SA : IBA Signs Contract with UZ Leuven to Install the First Proton Therapy Center in Belgium
25 Mars 2016 - 7:00AM
IBA Signs Contract
with UZ Leuven
to Install the First Proton Therapy Center in Belgium
Louvain-la-Neuve,
Belgium, March 25, 2016 - IBA (Ion Beam Applications SA), the
world's leading provider of proton therapy solutions for the
treatment of cancer, announces today that it has signed a contract
with the University Hospitals Leuven (UZ Leuven) and Katholieke
Universiteit Leuven (KU Leuven) to install Belgium's first proton
therapy center in a project with Université Catholique de Louvain
(UCL), Cliniques universitaires Saint-Luc and other Belgian
universities. IBA was awarded the contract following a
comprehensive European public tender conducted by UZ Leuven.
IBA will equip the new center with
its Proteus®ONE*
system. The contract will also include a long-term maintenance
agreement. The typical end-user price for a Proteus®ONE system
with such a maintenance contract is between EUR 35 and 40 million.
This new center is expected to open in 2018.
Olivier Legrain,
Chief Executive Officer of IBA commented: "We
are excited to have been selected to install Belgium's first proton
therapy center, bringing access to the most advanced radiation
therapy technology to Belgian cancer patients. We are proud to
install our cutting edge Proteus®ONE system so
close to our headquarters and we look forward to collaborating with
leading institutions like UZ Leuven, KU Leuven, UCL, Saint-Luc, and
the other Belgian universities involved in the
project."
Marc Decramer,
Chief Executive Officer of UZ Leuven commented: "We are very pleased to announce
that we will be working with IBA. The UZ Leuven mission is to
deliver the highest quality and most innovative patient care with
unrelenting attention to clinical excellence, patient care and
patient safety. It was therefore a natural decision for us to equip
our hospital with a proton therapy solution as it is the most
targeted treatment in the fight against cancer. Following a
comprehensive public tender, we have chosen IBA because it provided
the proton therapy solution that best fitted our needs."
- ENDS -
Notes to Editors
About Proton
Therapy
Proton Therapy is considered the most advanced and targeted cancer
treatment due to its superior dose distribution and fewer side
effects. Protons deposit the majority of their effective energy
within a precisely controlled range, directly within the tumor,
sparing healthy surrounding tissue. Higher doses can be delivered
to the tumor without increasing the risk of side effects and
long-term complications, thereby improving patient outcomes and
quality of life.
Today, more than half of all
proton therapy clinical facilities worldwide are equipped with IBA
systems. This includes 22 proton therapy centers currently in
operation and 18 additional centers under development. Over 50,000
patients have been treated with IBA equipment, which is more than
all major competitive installations combined.
About
Proteus®ONE
Proteus®ONE comprises
the latest technologies in proton therapy, which makes it the ideal
platform for research and development purposes. Proteus®ONE is
smaller, more affordable, easier to install, operate and ultimately
finance. All these advantages make this therapy solution accessible
to more and more healthcare institutions worldwide.
Proteus®ONE is
equipped with Pencil Beam Scanning, a technology that offers a
millimeter precision treatment, delivered with very high levels of
conformity and dose uniformity, even in complex-shaped tumors,
whilst at the same time sparing the surrounding healthy tissue.
*Proteus®ONE is the
brand name of a new configuration of the Proteus®
235
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry.
Headquartered in Belgium and
employing about 1200 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange
EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more
information can be found at: www.iba-worldwide.com
About UZ
Leuven
There are 1,955 beds in the University Hospitals Leuven, making it
the largest university hospital in Belgium. Every day, more than
9,000 enthusiastic employees do their utmost to provide diverse and
specialist patient care and work continuously on improving and
updating that care. The University Hospitals Leuven's strength lies
in combining top quality patient care, excellent innovative
scientific research and high-standing academic training. It was
also the first Belgian hospital to acquire the international JCI
label for safe and quality care. More information can be found
at: www.uzleuven.be
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com
|
Contact UZ
Leuven
Communication Department:
+32 16 34 49 55 or +32 16 34 49 85
communicatie@uzleuven.be
PR UZ_Leuven-EN-25.03.16
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#1997614
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024